Taro Pharmaceutical Industries (NYSE:TARO) released its quarterly earnings results on Wednesday. The company reported ($11.37) earnings per share for the quarter, missing the consensus estimate of $1.16 by ($12.53), MarketWatch Earnings reports. The company had revenue of $117.63 million during the quarter, compared to the consensus estimate of $158.35 million. Taro Pharmaceutical Industries had a negative net margin of 42.73% and a positive return on equity of 10.00%.

Shares of TARO stock opened at $65.01 on Friday. Taro Pharmaceutical Industries has a 12 month low of $56.07 and a 12 month high of $99.69. The stock has a market cap of $2.45 billion, a PE ratio of 11.87 and a beta of 0.79. The company’s fifty day moving average price is $66.23 and its 200-day moving average price is $69.27.

A number of brokerages have recently commented on TARO. HC Wainwright dropped their target price on shares of Taro Pharmaceutical Industries from $96.00 to $82.00 and set a “buy” rating on the stock in a report on Monday, July 27th. ValuEngine cut shares of Taro Pharmaceutical Industries from a “hold” rating to a “sell” rating in a report on Thursday, June 4th. Finally, Zacks Investment Research upgraded shares of Taro Pharmaceutical Industries from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 22nd.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.

Further Reading: Cash Asset Ratio

Earnings History for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.